Arcutis director Terrie Curran sells $956k in shares

Arcutis Biotherapeutics director Terrie Curran divested $956,122 worth of company shares on August 27, 2026. The sale comprised 38,200 shares, divided into two transactions. In the first, Curran offloaded 11,148 shares at an average price of $25.0294, generating proceeds of $279,027. The second transaction saw the sale of 27,052 shares, also at the same weighted average price, yielding $677,095 in revenue.

The shares traded within a $25.00 to $25.1001 price bracket, representing a premium over the stock's current price of $23.78, which InvestingPro analysis deems undervalued. Prior to these sales, Curran had bought the same quantity of shares through stock option exercises. Upon exercising those options, she acquired 11,148 shares at $7.51 per share, costing $83,721, and another 27,052 shares at $8.63 each, totaling $233,458.

After these transactions, Curran holds 23,526 shares of Arcutis common stock. For investors interested in a more detailed analysis of ARQT’s financials and growth potential, InvestingPro provides a Pro Research Report with 15 exclusive tips. Additionally, Arcutis Biotherapeutics reported a robust second-quarter 2026 revenue of $129.9 million, surpassing analyst estimates and marking a significant increase from both the previous year and the preceding quarter.

This growth, largely attributed to the successful sales of their product Zoryve, has propelled the company into profitability. Following these results, Guggenheim raised its price target for Arcutis from $35 to $38, citing solid sales performance and pricing improvements.